d16:1

Sphingosine (d16:1), an unconventional sphingolipid, is synthesized through enzymatic reactions starting with the condensation of myristoyl-CoA and serine by serine palmitoyltransferase long-chain base subunit 3 (SPTLC3), which shows a preference for myristoyl-CoA. This compound is found in minute quantities in its free form in human plasma and as a component of various plasma sphingolipids, such as sphingosine-1-phosphate, ceramides, sphingomyelins, and in brain cerebrosides, albeit at lower concentrations than the more common d18:1 sphingoid base. Sphingosine (d16:1) acts as an inhibitor of PKC in mixed micelle assays and diminishes superoxide production triggered by phorbol 12-myristate 13-acetate in isolated human neutrophils, as well as inhibiting the growth of CHO cells with IC50 values of 1 and 3.2 µM, respectively. Additionally, the concentration of sphingolipids containing sphingosine (d16:1) in the plasma is linked to the dietary consumption of saturated fatty acids and protein among ethnic Chinese populations.

C16 Ceramide (d16:1,C16:0) is a bioactive sphingolipid that induces the formation and thermal stabilization of ordered phases and gel phases enriched in palmitoyl sphingomyelin domains within palmitoyl phosphatidylcholine (POPC) bilayers. It is found in human erythrocyte sphingomyelin.

C16 Sphingosine-1-phosphate (C16 S1P) is a derivative of sphingosine-1-phosphate that binds to S1P1/EDG-1, S1P3/EDG-3, and S1P2/EDG-5 receptors with affinities of 115%, 83%, and 103%, respectively, relative to S1P in CHO cells. C16 S1P was increased in postmortem primary open angle glaucoma trabecular meshwork samples.

CD161 is a potent, selective, and orally bioavailable BET bromodomain inhibitor (IC50s: 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2) with good anticancer activity.

ZD-1611 is an effective and selective ETA receptor antagonist. It is used for the research of ischemic stroke.

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. It also inhibits the PDGFR, EGFR, and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.

CID16197121 is a bioactive chemical.

EIDD-1619 is a novel water-soluble analog of progesterone.

PD 161182 is a bioactive chemical.

DD-161515 is a VR1 antagonist.

ALD1613 is a potent neutralizing monoclonal antibody targeting adrenocorticotropic hormone (ACTH). It neutralizes ACTH-induced signaling and inhibits cyclic adenosine monophosphate accumulation in ACTH-stimulated Y1 (mouse adrenal cell line) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats and is applicable in studies involving elevated ACTH-related conditions.

Palmitic acid-16,16,16-d3 is a deuterated compound of Palmitic acid. Palmitic acid has a CAS number of 57-10-3. Palmitic acid is the most common saturated fatty acid found in animals, plants and microorganisms with anti-tumor activity.

(10alpha)-16alpha,17,19-Trihydroxykaurane-18-oic acid is a natural product

Compound D16 (Anticancer agent 168) is an inhibitor of DNA2 that induces apoptosis and cell-cycle arrest predominantly in the S-phase. It demonstrates anticancer efficacy and can counteract chemotherapy resistance in cancers harboring mutant p53 [1].